IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibikase Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.65−0.00 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $287.17M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -107.6% | -36.0% | |
| Return on assets | – | – | -34.5% | |
| Current ratio | – | 3.13 | 21.70 | |
| Debt to equity | – | 0.03 | – | |
| Interest coverage | – | -95.9× | – | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 1M | 98M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Inhibikase Therapeutics generated $96.67M from operations and spent $270.89K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$96.67M
Used
$270.89K
Capital expenditure$270.89K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7304.7%
×Asset turnover0.01×
×Equity multiplier1.23×
=Return on equity, FY2023-118.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -7304.7% | 0.01× | 1.23× | -118.9% |
| FY2022 | -14625.9% | 0.00× | 1.13× | -60.7% |
| FY2021 | -476.9% | 0.11× | 1.19× | -61.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$48.26M
- Cash generatingOperating cash flow above zero-$27.79M
- Return on assets improvedROA up on the prior year-189.7% → -48.9%
- Earnings backed by cashOperating cash flow above net income-$27.79M vs -$48.26M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose26.37 → 21.70
- No dilutionShare count did not rise24M → 98M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → –